Tenapanor Under Review for Hyperphosphatemia in CKD
Tenapanor is a first-in-class oral medication that works by blocking the NHE3 transporter in the gastrointestinal tract.
Urologic Disorders
FDA Rejects Terlipressin NDA for Hepatorenal Syndrome Type 1
In July 2020, the FDA Cardiovascular and Renal Drugs Advisory Committee narrowly voted 8 to 7 in favor of the approval of terlipressin for HRS-1.
Guideline Updated for Nutrition in Chronic Kidney Disease
Updated guidelines expanded to include patients with stage 1 to 5 CKD, those with kidney transplant.
FDA Cites Deficiencies in Veverimer NDA for Metabolic Acidosis in CKD
Veverimer is a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD.
Intravaginal Home-Use Device Cleared for Stress Urinary Incontinence
Flyte is an in-home treatment designed to strengthen and treat weakened pelvic floor muscles.
Ferric Citrate May Improve Iron Parameters Better Than Ferrous Sulfate in CKD
Transferrin saturation and ferritin concentrations improved significantly more in the ferric citrate than ferrous sulfate group over 12 weeks.
No Cap on Damages in a Medical Battery Case, Says CA Court
Prior to the procedure, Mr K filled out 2 surgical consent forms, both describing the intended procedure as “local excision of a scrotal mass, possible cystoscopy.”
Orphan Drug Status Granted to Potential Polycystic Kidney Disease Treatment
Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations of the PKD1 and PKD2 genes.
Trial Investigating Dapagliflozin in CKD Meets All End Points
The multicenter, event-driven, double-blind, placebo-controlled trial compared the effect of dapagliflozin to placebo on renal outcomes and cardiovascular mortality in patients with CKD.
Recommendations Updated for Barrier Method Use Among Teens
American Academy of Pediatrics policy statement updated recommendations are presented relating to use of barrier methods for adolescents engaging in sexual activity.
